Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial
Source: View publication →
In patients with biochemical recurrence after radical prostatectomy, hypofractionated salvage radiotherapy did not demonstrate superior 4-year biochemical progression-free survival compared to standard conventional radiotherapy, though both regimens yielded similar oncologic outcomes with comparable patient-reported quality of life.
Key Findings
Study Design
Study Limitations
Clinical Significance
While hypofractionated radiotherapy did not achieve statistical superiority, its comparable oncologic control and manageable toxicity profile support its use as a viable alternative to conventional radiotherapy in the post-prostatectomy salvage setting. By significantly reducing the required number of treatment sessions (26 versus 33 fractions), hypofractionation lessens the logistical burden on patients and optimizes health system resources without compromising quality of life.
Historical Context
For decades, standard fractionated radiotherapy (delivering 1.8 to 2.0 Gy per day) was the mainstay for post-prostatectomy salvage treatment. Given the characteristically low alpha/beta ratio of prostate adenocarcinoma, hypofractionation—which delivers higher doses per fraction over fewer total sessions—gained traction and became a standard of care for definitive, primary prostate radiotherapy (validated by trials like CHHiP and PROFIT). However, its adoption in the postoperative salvage setting lagged due to fears of heightened genitourinary and gastrointestinal toxicity when irradiating the surgical bed. The SHARE trial (NCT03920033) was developed to formally evaluate the efficacy and safety of hypofractionation specifically for post-surgical biochemical recurrence.
Guided Discussion
High-yield insights from every perspective
What is the radiobiological rationale behind using hypofractionated radiotherapy for prostate cancer, specifically relating to the alpha/beta ratio?
Key Response
Prostate cancer is thought to have a low alpha/beta ratio (often estimated around 1.5-3 Gy), meaning it is highly sensitive to the fraction size of radiation. Hypofractionation delivers higher doses per fraction over a shorter time, theoretically maximizing tumor cell kill while sparing surrounding tissues with higher alpha/beta ratios.
Given that hypofractionated salvage RT did not show superior biochemical progression-free survival but had similar oncologic and QoL outcomes, how does this influence your shared decision-making with a patient presenting with biochemical recurrence post-prostatectomy?
Key Response
Since outcomes and QoL are comparable, the discussion should center on convenience, cost, and logistics. Hypofractionation requires fewer visits, significantly reducing the logistical and financial burden on the patient and the healthcare system, making it a highly attractive option despite the lack of oncologic superiority.
In evaluating the failure to demonstrate superiority in this trial, how might concurrent androgen deprivation therapy (ADT) use and the timing of salvage RT (e.g., PSA level at initiation) confound or dilute the potential bPFS benefit of hypofractionation?
Key Response
The use of concurrent ADT is standard for many high-risk SRT patients and significantly impacts bPFS. If a large proportion of patients received ADT, its systemic effect might mask a local control benefit from altered fractionation. Furthermore, initiating SRT at very low PSA levels might yield excellent outcomes in both arms, leaving little room to demonstrate statistical superiority.
If we accept hypofractionation as a viable standard for salvage RT based on equivalent toxicity and oncologic control, what specific normal tissue constraints and target volume delineations must we adapt in our clinics to ensure we do not inadvertently increase late genitourinary or gastrointestinal toxicity?
Key Response
Shifting from standard to hypofractionated salvage RT requires strict adherence to modified dose constraints and highly precise image guidance (IGRT). Attendings must ensure their clinical workflow, contouring protocols, and QA processes are updated to safely deliver higher doses per fraction to the post-prostatectomy bed without increasing late toxicity.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The study was designed to test for superiority but concluded similar oncologic outcomes. From a statistical and trial design perspective, what are the perils of interpreting a failed superiority trial as evidence of equivalence or non-inferiority?
Key Response
A failed superiority trial does not automatically imply non-inferiority because it may lack the statistical power, appropriate predefined non-inferiority margins, and per-protocol analyses required to confidently rule out a clinically meaningful worse outcome. Claiming equivalence from a non-significant p-value in a superiority framework is a classic statistical fallacy.
As a reviewer evaluating this Phase III trial, how would you scrutinize the choice of the primary endpoint (4-year bPFS) and the follow-up duration regarding its validity as a surrogate for metastasis-free survival (MFS) or overall survival (OS) in the salvage setting?
Key Response
Prostate cancer has a long natural history, especially in the salvage setting. A 4-year bPFS endpoint might be too early to capture meaningful differences in late clinical events like MFS, OS, or late-onset (>5 years) radiation toxicity. A tough reviewer would flag the short follow-up as a significant limitation in definitively establishing long-term safety and efficacy.
Currently, ASTRO/AUA guidelines present conventionally fractionated SRT as the standard, with hypofractionation often considered as an alternative. Does this trial's finding of comparable outcomes and QoL provide sufficient Level 1 evidence to formally upgrade hypofractionated SRT to a standard-of-care recommendation equivalent to conventional fractionation?
Key Response
While the trial failed to show superiority, the comparable bPFS and QoL are compelling. The committee must weigh whether a 'failed superiority' trial provides strong enough evidence, perhaps in combination with other recent non-inferiority trials, to change guidelines to equally endorse hypofractionation (saving resources) while explicitly defining the required technical standards for its safe delivery.
Clinical Landscape
Noteworthy Related Trials
CHHiP Trial
Tested
Hypofractionated radiotherapy (60 Gy in 20 fractions)
Population
Men with localized prostate cancer
Comparator
Standard fractionated radiotherapy (74 Gy in 37 fractions)
Endpoint
Biochemical or clinical failure
RTOG 9601
Tested
Salvage radiotherapy plus 24 months of bicalutamide
Population
Men with biochemical recurrence after radical prostatectomy
Comparator
Salvage radiotherapy plus placebo
Endpoint
Overall survival
RADICALS-RT
Tested
Early salvage radiotherapy upon biochemical progression
Population
Men at risk of recurrence after radical prostatectomy
Comparator
Adjuvant radiotherapy
Endpoint
Freedom from distant metastases
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis